VLP Therapeutics awarded Phase 1 SBIR grant to support novel virus-like particle vaccine-based cancer immunotherapy.
M2 PHARMA-October 12, 2017-VLP Therapeutics awarded Phase 1 SBIR grant to support novel virus-like particle vaccine-based cancer immunotherapy
(C)2017 M2 COMMUNICATIONS
Biotechnology company VLP Therapeutics LLC reported on Wednesday the receipt of USD298,729 Phase I grant from the National Cancer Institute under auspices of the Small Business Innovation Research (SBIR) programme of the National Institutes of Health.
Under the Award Number R43CA217445, the SBIR Phase I grant will focus on "the development of a novel Virus-Like Particle vaccine-based cancer immunotherapy targeting PD-L1" as well as explore broader immune checkpoint inhibition mechanisms, added the company.
The company will use the SBIR grant to support its collaboration with Louis M Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University.
According to the company, the research will focus on determining immune response in mice and includes support for proof-of-concept studies at the Georgetown Lombardi. Weiner, an expert in cancer immunotherapeutics, is an unpaid member of the VLP Scientific Advisory Board.
Unlike traditional vaccines, the company's novel, proprietary virus-like particles are identical to the authentic native viruses in their shapes, but do not carry the genetic material of native viruses. Hence, when the virus-like particles are presented within our bodies, the immune system will recognise the particles as foreign objects, triggering effective immune responses, concluded the company.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 12, 2017|
|Previous Article:||Upsher-Smith unveils generic Aromasin (Exemestane) Tablet in the US.|
|Next Article:||Samsung BioLogics awarded first US FDA approval at the world's largest biologics drug substance plant.|